Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase II Dose Titration Study in Patients With Neuropathic Pain

This study has been completed.
Information provided by:
Newron Identifier:
First received: August 13, 2008
Last updated: August 6, 2009
Last verified: August 2009
The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.

Condition Intervention Phase
Neuropathic Pain
Drug: Ralfinamide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Basic Science
Official Title: A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain

Further study details as provided by Newron:

Primary Outcome Measures:
  • Change of pain intensity [ Time Frame: Baseline to week 8 or last visit ]

Secondary Outcome Measures:
  • The incidence of adverse events [ Time Frame: From baseline to week 8 or last visit ]

Enrollment: 272
Study Start Date: May 2004
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Ralfinamide administered orally at rising doses of 80 - 320 mg/day
Drug: Ralfinamide
Oral tablets administered at rising doses of 80 - 320 mg/day
Active Comparator: 2
Placebo controlled with randomization of 2:1
Drug: Ralfinamide
Oral tablets administered at rising doses of 80 - 320 mg/day


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients
  • Females post-menopausal for at least 12 months, 24 months in India, Poland, and Austria
  • Diagnosed by neurologist with current neuropathic pain

Exclusion Criteria:

  • See inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00736151

  Show 47 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Stefano Rossetti, MD, Newron Pharmaceuticals S.p.A Identifier: NCT00736151     History of Changes
Other Study ID Numbers: NW-1029/001/II/2003
EUDRACT Number 2004-000557-35
Study First Received: August 13, 2008
Last Updated: August 6, 2009

Additional relevant MeSH terms:
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms processed this record on May 25, 2017